Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23671488 | 0.95 | BACE1 (0.68) | BACE1KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL21616850 | 0.94 | BACE1 (0.74) | BACE1KDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL23671498 | 0.94 | BACE1 (0.71) | BACE1KDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL23671502 | 0.91 | BACE1 (0.69) | BACE1KDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL21622470 | 0.81 | BACE1 (1.00) | BACE1 | |
| SCHEMBL21616824 | 0.78 | BACE1 (1.00) | BACE1 | |
| SCHEMBL21616855 | 0.78 | BACE1 (0.85) | BACE1 | |
| SCHEMBL21616831 | 0.78 | BACE1 (0.77) | BACE1 | |
| SCHEMBL23671506 | 0.78 | BACE1 (0.76) | BACE1 | |
| SCHEMBL21616860 | 0.77 | BACE1 (1.00) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) (FR) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230131-A1 | POLYAMINO BIARYL COMPOUNDS AND THEIR USE | ABCG2, SLC10A1, CYP3A43 | BACE1 1582/4885KDM4E 3694/4885SMN1; SMN2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.